JP2012500286A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012500286A5 JP2012500286A5 JP2011523987A JP2011523987A JP2012500286A5 JP 2012500286 A5 JP2012500286 A5 JP 2012500286A5 JP 2011523987 A JP2011523987 A JP 2011523987A JP 2011523987 A JP2011523987 A JP 2011523987A JP 2012500286 A5 JP2012500286 A5 JP 2012500286A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- cancer
- moiety
- antibody
- dnl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9048708P | 2008-08-20 | 2008-08-20 | |
| US61/090,487 | 2008-08-20 | ||
| PCT/US2009/054441 WO2010022225A1 (en) | 2008-08-20 | 2009-08-20 | Dock-and-lock (dnl) vaccines for cancer therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012500286A JP2012500286A (ja) | 2012-01-05 |
| JP2012500286A5 true JP2012500286A5 (cg-RX-API-DMAC10.html) | 2012-09-20 |
| JP5870404B2 JP5870404B2 (ja) | 2016-03-01 |
Family
ID=41707458
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011523987A Active JP5870404B2 (ja) | 2008-08-20 | 2009-08-20 | 癌治療のためのドック・ロック(dnl)ワクチン |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US7901680B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP2326346A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP5870404B2 (cg-RX-API-DMAC10.html) |
| CN (1) | CN102186499B (cg-RX-API-DMAC10.html) |
| AU (1) | AU2009282830B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2734265C (cg-RX-API-DMAC10.html) |
| WO (1) | WO2010022225A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7550143B2 (en) * | 2005-04-06 | 2009-06-23 | Ibc Pharmaceuticals, Inc. | Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses |
| US7666400B2 (en) | 2005-04-06 | 2010-02-23 | Ibc Pharmaceuticals, Inc. | PEGylation by the dock and lock (DNL) technique |
| US7527787B2 (en) * | 2005-10-19 | 2009-05-05 | Ibc Pharmaceuticals, Inc. | Multivalent immunoglobulin-based bioactive assemblies |
| US8383081B2 (en) * | 1999-05-10 | 2013-02-26 | Immunomedics, Inc. | Anti-CD74 immunoconjugates and methods of use |
| US7534866B2 (en) | 2005-10-19 | 2009-05-19 | Ibc Pharmaceuticals, Inc. | Methods and compositions for generating bioactive assemblies of increased complexity and uses |
| KR101017732B1 (ko) * | 2002-03-01 | 2011-02-28 | 이뮤노메딕스, 인코오포레이티드 | 내재화 항-cd74 항체 및 그 이용방법 |
| US20160279239A1 (en) | 2011-05-02 | 2016-09-29 | Immunomedics, Inc. | Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease |
| US7906118B2 (en) | 2005-04-06 | 2011-03-15 | Ibc Pharmaceuticals, Inc. | Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology |
| US8491914B2 (en) * | 2004-02-13 | 2013-07-23 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (DNL) complexes for delivery of interference RNA |
| US8883160B2 (en) * | 2004-02-13 | 2014-11-11 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (DNL) complexes for therapeutic and diagnostic use |
| US8435539B2 (en) * | 2004-02-13 | 2013-05-07 | Immunomedics, Inc. | Delivery system for cytotoxic drugs by bispecific antibody pretargeting |
| US8003111B2 (en) * | 2005-04-06 | 2011-08-23 | Ibc Pharmaceuticals, Inc. | Dimeric alpha interferon pegylated site-specifically shows enhanced and prolonged efficacy in vivo |
| US8652484B2 (en) | 2004-02-13 | 2014-02-18 | Immunomedics, Inc. | Delivery system for cytotoxic drugs by bispecific antibody pretargeting |
| US8034352B2 (en) * | 2005-04-06 | 2011-10-11 | Ibc Pharmaceuticals, Inc. | Tetrameric cytokines with improved biological activity |
| US20110020273A1 (en) * | 2005-04-06 | 2011-01-27 | Ibc Pharmaceuticals, Inc. | Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof |
| US9550838B2 (en) | 2004-02-13 | 2017-01-24 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (DNL) complexes for therapeutic and diagnostic use |
| US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
| US8481041B2 (en) | 2005-04-06 | 2013-07-09 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (DNL) constructs for human immunodeficiency virus (HIV) therapy |
| US8158129B2 (en) * | 2005-04-06 | 2012-04-17 | Ibc Pharmaceuticals, Inc. | Dimeric alpha interferon PEGylated site-specifically shows enhanced and prolonged efficacy in vivo |
| US8067006B2 (en) | 2005-04-06 | 2011-11-29 | Immunomedics, Inc. | Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites |
| US8475794B2 (en) | 2005-04-06 | 2013-07-02 | Ibc Pharmaceuticals, Inc. | Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases |
| US9623115B2 (en) | 2005-04-06 | 2017-04-18 | Ibc Pharmaceuticals, Inc. | Dock-and-Lock (DNL) Complexes for Disease Therapy |
| US8349332B2 (en) | 2005-04-06 | 2013-01-08 | Ibc Pharmaceuticals, Inc. | Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases |
| US9931413B2 (en) | 2005-04-06 | 2018-04-03 | Ibc Pharmaceuticals, Inc. | Tetrameric cytokines with improved biological activity |
| CA2604032C (en) * | 2005-04-06 | 2017-08-22 | Ibc Pharmaceuticals, Inc. | Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses |
| US9862770B2 (en) | 2005-10-19 | 2018-01-09 | Ibc Pharmaceuticals, Inc. | Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors |
| US20100226884A1 (en) | 2009-01-20 | 2010-09-09 | Immunomedics, Inc. | Novel Class of Monospecific and Bispecific Humanized Antibodies that Target the Insulin-like Growth Factor Type I Receptor (IGF-1R) |
| WO2012024223A2 (en) * | 2010-08-17 | 2012-02-23 | Immunomedics, Inc. | Combination therapy with anti-cd74 antibodies provides enhanced toxicity to malignancies, autoimmune disease and other diseases |
| US9272029B2 (en) | 2009-03-26 | 2016-03-01 | Ibc Pharmaceuticals, Inc. | Interferon lambada-antibody complexes |
| WO2010022225A1 (en) * | 2008-08-20 | 2010-02-25 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (dnl) vaccines for cancer therapy |
| ES2550384T3 (es) | 2008-12-18 | 2015-11-06 | Dana-Farber Cancer Institute, Inc. | NKG2D-Fc para la inmunoterapia |
| WO2010117984A1 (en) * | 2009-04-10 | 2010-10-14 | Immunomedics, Inc. | Novel strategies for improved cancer vaccines |
| WO2011066454A1 (en) * | 2009-11-24 | 2011-06-03 | Inviragen, Inc. | Compositions, methods and uses for expression of enterobacterium-associated peptides |
| EP2552483A4 (en) * | 2010-04-01 | 2013-09-25 | Immunomedics Inc | USE OF ANTIBODIES TO REDUCE THE NUMBER OF CELLS CONTAINING ANTIGENS AND DENDRITIC CELLS |
| EP2635300A4 (en) * | 2010-11-03 | 2014-04-02 | Ibc Pharmaceuticals Inc | DOCK-AND-LOCK (DNL) CONSTRUCTS FOR THERAPY AGAINST HUMAN IMMUNE WEAKAGE VIRUS (HIV) |
| US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
| US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
| US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
| US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
| US9783601B2 (en) | 2010-12-01 | 2017-10-10 | Alderbio Holdings Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
| US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
| AU2012250924B2 (en) | 2011-05-02 | 2017-05-25 | Immunomedics, Inc. | Ultrafiltration concentration of allotype selected antibodies for small-volume administration |
| MX359411B (es) | 2012-01-13 | 2018-09-27 | Univ Wuerzburg J Maximilians | Complementación funcional bipartita inducida por antígenos, dual. |
| JP6205621B2 (ja) * | 2012-01-26 | 2017-10-04 | アイビーシー ファーマスーティカルズ,インコーポレイテッド | 抗体を有するインターフェロンλでの標的化は抗腫瘍および抗ウイルス活性を大きく増強する |
| US20150132302A1 (en) * | 2012-05-01 | 2015-05-14 | The University Of Sydney | Vaccine and uses thereof |
| CN104363919A (zh) * | 2012-06-01 | 2015-02-18 | Ibc药品公司 | 具有改进的体内稳定性、药物代谢动力学和功效的多聚体复合物 |
| US9682143B2 (en) | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| US9382329B2 (en) | 2012-08-14 | 2016-07-05 | Ibc Pharmaceuticals, Inc. | Disease therapy by inducing immune response to Trop-2 expressing cells |
| AU2013302696B9 (en) | 2012-08-14 | 2018-08-09 | Ibc Pharmaceuticals, Inc. | T-cell redirecting bispecific antibodies for treatment of disease |
| US10131712B2 (en) | 2012-08-14 | 2018-11-20 | Ibc Pharmaceuticals, Inc. | Combination therapy with T-cell redirecting bispecific antibodies and checkpoint inhibitors |
| US20150231241A1 (en) | 2012-08-14 | 2015-08-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| GB201216002D0 (en) | 2012-09-07 | 2012-10-24 | Deutsches Rheuma Forschungszentrum Berlin Drfz | Compositions adn methods |
| CN107753954A (zh) | 2012-12-13 | 2018-03-06 | 免疫医疗公司 | 功效改进且毒性降低的抗体与sn‑38的免疫缀合物的剂量 |
| CN103131710B (zh) * | 2013-03-05 | 2014-12-17 | 西藏自治区人民医院 | 一种抑制肿瘤细胞侵袭的shRNA |
| CA2924520C (en) | 2013-11-01 | 2023-09-26 | Ibc Pharmaceuticals, Inc. | Bispecific antibodies that neutralize both tnf-alpha and il-6: novel therapeutic agent for autoimmune disease |
| CN103739714B (zh) * | 2013-12-30 | 2016-06-01 | 江苏众红生物工程创药研究院有限公司 | TNFα与DC-SIGN的融合蛋白及其应用 |
| ES2978993T3 (es) | 2014-02-21 | 2024-09-23 | Ibc Pharmaceuticals Inc | Terapia de enfermedades mediante la inducción de la respuesta inmunitaria a las células que expresan Trop-2 |
| WO2016033163A1 (en) * | 2014-08-29 | 2016-03-03 | Immunomedics, Inc. | Identification of cancer genes by in-vivo fusion of human cancer cells and animal cells |
| US10494425B2 (en) | 2015-02-24 | 2019-12-03 | Rpeptide, Llc | Anti-amyloid-beta antibodies |
| CN107614515B (zh) * | 2015-05-28 | 2022-03-22 | 免疫医疗公司 | 用于抗hiv(人免疫缺陷病毒)疗法和/或疫苗的t20构建体 |
| PT3313443T (pt) | 2015-06-25 | 2023-08-30 | Immunomedics Inc | Combinação de anticorpos anti-hla-dr ou anti-trop-2 com inibidores de microtúbulos, inibidores de parp, inibidores de bruton quinase ou inibidores de fosfoinositídeo 3-quinase melhora significativamente o resultado terapêutico no cancro |
| CN114853907B (zh) | 2015-11-13 | 2025-06-27 | 达纳-法伯癌症研究所有限公司 | 用于癌症免疫疗法的nkg2d-ig融合蛋白 |
| US10669338B2 (en) | 2016-06-17 | 2020-06-02 | Immunomedics, Inc. | Anti-PD-1 checkpoint inhibitor antibodies that block binding of PD-L1 to PD-1 |
| CA3044082A1 (en) | 2017-04-03 | 2018-10-11 | Immunomedics, Inc. | Subcutaneous administration of antibody-drug conjugates for cancer therapy |
| CN108379567A (zh) * | 2018-02-28 | 2018-08-10 | 宁夏医科大学 | 抗黑色素瘤纳米颗粒疫苗及其制备与应用 |
| WO2020172233A1 (en) * | 2019-02-22 | 2020-08-27 | The Trustees Of Columbia University In The City Of New York | Treatment of prostate cancer by androgen ablation and il-8 blockade |
| CN118541392A (zh) | 2021-09-28 | 2024-08-23 | 准星生物医药有限公司 | 多种形式的分子复合物 |
| CN119816521A (zh) * | 2022-09-23 | 2025-04-11 | 准星生物医药有限公司 | 具有多种功能或结合特异性的分子嫁接免疫球蛋白 |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1541435A (en) * | 1975-02-04 | 1979-02-28 | Searle & Co | Immunological materials |
| US4818709A (en) * | 1983-01-21 | 1989-04-04 | Primus Frederick J | CEA-family antigens, Anti-CEA antibodies and CEA immunoassay |
| US5614610A (en) * | 1984-12-21 | 1997-03-25 | Oncogen | Tumor immunotherapy using anti-idiotypic antibodies |
| US5851526A (en) | 1985-04-19 | 1998-12-22 | Ludwig Institute For Cancer Research | Methods of treating colon cancer utilizing tumor-specific antibodies |
| NL8501219A (nl) * | 1985-04-29 | 1986-11-17 | Stichting Vrienden Van De Stic | Immunologisch complex, de bereiding en toepassing daarvan. |
| US4699784A (en) * | 1986-02-25 | 1987-10-13 | Center For Molecular Medicine & Immunology | Tumoricidal methotrexate-antibody conjugate |
| US5194254A (en) * | 1986-05-06 | 1993-03-16 | Connaught Laboratories Limited | Enhancement of antigen immunogenicity |
| DK8189A (da) | 1988-01-12 | 1989-07-13 | Bunge Australia | Antigen-antistof-konjugater, deres fremstilling og anvendelse |
| IL86278A (en) | 1988-05-04 | 2003-06-24 | Yeda Res & Dev | Endowing cells with antibody specificity using chimeric t cell receptor |
| US5770198A (en) * | 1988-05-18 | 1998-06-23 | The Research Foundation Of The State Of New York | Platelet-specific chimeric 7E3 immunoglobulin |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP1001032A3 (en) * | 1989-08-18 | 2005-02-23 | Chiron Corporation | Recombinant retroviruses delivering vector constructs to target cells |
| DE69030172T2 (de) * | 1990-01-26 | 1997-06-19 | Immunomedics Inc | Impfstoffe gegen Krebs und Infektionskrankheiten |
| IE920716A1 (en) | 1991-03-07 | 1992-09-09 | Gen Hospital Corp | Redirection of cellular immunity by receptor chimeras |
| US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
| WO1994005329A1 (en) | 1992-08-31 | 1994-03-17 | Jenner Technologies | Stimulation of an antitumor t-cell response using anti-idiotypic antibodies |
| US5478556A (en) * | 1994-02-28 | 1995-12-26 | Elliott; Robert L. | Vaccination of cancer patients using tumor-associated antigens mixed with interleukin-2 and granulocyte-macrophage colony stimulating factor |
| US5571515A (en) * | 1994-04-18 | 1996-11-05 | The Wistar Institute Of Anatomy & Biology | Compositions and methods for use of IL-12 as an adjuvant |
| US7354587B1 (en) * | 1994-07-06 | 2008-04-08 | Immunomedics, Inc. | Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines |
| US5798100A (en) * | 1994-07-06 | 1998-08-25 | Immunomedics, Inc. | Multi-stage cascade boosting vaccine |
| US5686578A (en) | 1994-08-05 | 1997-11-11 | Immunomedics, Inc. | Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype |
| US5874540A (en) * | 1994-10-05 | 1999-02-23 | Immunomedics, Inc. | CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies |
| US20030198956A1 (en) * | 2002-02-21 | 2003-10-23 | Lee Makowski | Staged assembly of nanostructures |
| US20040018587A1 (en) * | 1994-10-13 | 2004-01-29 | Lee Makowski | Nanostructures containing antibody assembly units |
| US5871945A (en) | 1994-11-23 | 1999-02-16 | Icos Corporation | Modulators of anchoring protein function |
| DE69637523D1 (de) * | 1995-06-07 | 2008-06-26 | Sanofi Pasteur Ltd | Chimäre antikörper zur abgabe von antigenen an selektierte zellen des immunsystems |
| US6261537B1 (en) * | 1996-10-28 | 2001-07-17 | Nycomed Imaging As | Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors |
| US8021666B2 (en) * | 1997-02-18 | 2011-09-20 | Sloan-Kettering Institute For Cancer Research | Method and compositions for stimulation of an immune response to CD20 using a xenogeneic CD20 antigen |
| US6306393B1 (en) * | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| EP0973916A1 (en) * | 1997-04-11 | 2000-01-26 | Dendreon Corporation | Composition and method for inducing an immune response against tumour-related antigens |
| US6756039B1 (en) | 1999-05-10 | 2004-06-29 | The Regents Of The University Of California | Self assembling proteins |
| US7527787B2 (en) * | 2005-10-19 | 2009-05-05 | Ibc Pharmaceuticals, Inc. | Multivalent immunoglobulin-based bioactive assemblies |
| US7666400B2 (en) * | 2005-04-06 | 2010-02-23 | Ibc Pharmaceuticals, Inc. | PEGylation by the dock and lock (DNL) technique |
| US7550143B2 (en) * | 2005-04-06 | 2009-06-23 | Ibc Pharmaceuticals, Inc. | Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses |
| US7534866B2 (en) * | 2005-10-19 | 2009-05-19 | Ibc Pharmaceuticals, Inc. | Methods and compositions for generating bioactive assemblies of increased complexity and uses |
| WO2001010912A1 (en) * | 1999-08-09 | 2001-02-15 | Lexigen Pharmaceuticals Corp. | Multiple cytokine-antibody complexes |
| US7030228B1 (en) * | 1999-11-15 | 2006-04-18 | Miltenyi Biotec Gmbh | Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby |
| US7060506B2 (en) * | 2000-01-31 | 2006-06-13 | Cyclacel, Ltd. | Compositions and methods for monitoring the modification of modification dependent binding partner polypeptides |
| US7560534B2 (en) | 2000-05-08 | 2009-07-14 | Celldex Research Corporation | Molecular conjugates comprising human monoclonal antibodies to dendritic cells |
| JP5007409B2 (ja) | 2000-05-08 | 2012-08-22 | セルデックス リサーチ コーポレーション | 樹状細胞に対するヒトモノクローナル抗体 |
| US6524854B1 (en) * | 2001-09-11 | 2003-02-25 | Isis Pharmaceuticals, Inc. | Antisense inhibition of PKA regulatory subunit RII alpha expression |
| CA2476166C (en) * | 2002-02-14 | 2011-11-15 | Immunomedics, Inc. | Anti-cd20 antibodies and fusion proteins thereof and methods of use |
| ATE421328T1 (de) * | 2002-02-22 | 2009-02-15 | Intracel Recources Llc | Sterile immunogene nicht-tumorigene tumorzell- zusammensetzungen und verfahren |
| US7591994B2 (en) * | 2002-12-13 | 2009-09-22 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
| KR101017732B1 (ko) * | 2002-03-01 | 2011-02-28 | 이뮤노메딕스, 인코오포레이티드 | 내재화 항-cd74 항체 및 그 이용방법 |
| CA2484676A1 (en) * | 2002-05-03 | 2003-11-13 | Sequenom, Inc. | Kinase anchor protein muteins, peptides thereof, and related methods |
| EP1511513A2 (en) * | 2002-06-11 | 2005-03-09 | GlaxoSmithKline Biologicals S.A. | Immunogenic compositions comprising a xenogenic prostate protein p501s |
| US7906118B2 (en) * | 2005-04-06 | 2011-03-15 | Ibc Pharmaceuticals, Inc. | Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology |
| US7541440B2 (en) * | 2002-09-30 | 2009-06-02 | Immunomedics, Inc. | Chimeric, human and humanized anti-granulocyte antibodies and methods of use |
| US20050003403A1 (en) * | 2003-04-22 | 2005-01-06 | Rossi Edmund A. | Polyvalent protein complex |
| US8491914B2 (en) * | 2004-02-13 | 2013-07-23 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (DNL) complexes for delivery of interference RNA |
| US20110020273A1 (en) * | 2005-04-06 | 2011-01-27 | Ibc Pharmaceuticals, Inc. | Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof |
| US8562988B2 (en) * | 2005-10-19 | 2013-10-22 | Ibc Pharmaceuticals, Inc. | Strategies for improved cancer vaccines |
| US8883160B2 (en) * | 2004-02-13 | 2014-11-11 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (DNL) complexes for therapeutic and diagnostic use |
| US8034352B2 (en) * | 2005-04-06 | 2011-10-11 | Ibc Pharmaceuticals, Inc. | Tetrameric cytokines with improved biological activity |
| US8551480B2 (en) * | 2004-02-13 | 2013-10-08 | Immunomedics, Inc. | Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity |
| US20110064754A1 (en) * | 2005-03-03 | 2011-03-17 | Center For Molecular Medicine And Immunology | Immunoconjugates Comprising Poxvirus-Derived Peptides and Antibodies Against Antigen-Presenting Cells for Subunit-Based Poxvirus Vaccines |
| US8003111B2 (en) * | 2005-04-06 | 2011-08-23 | Ibc Pharmaceuticals, Inc. | Dimeric alpha interferon pegylated site-specifically shows enhanced and prolonged efficacy in vivo |
| US7608425B2 (en) * | 2004-07-23 | 2009-10-27 | Immunomedics, Inc. | Methods for protein expression in mammalian cells in serum-free medium |
| CN101171034B (zh) * | 2005-03-03 | 2014-06-18 | 免疫医疗公司 | 人源化l243抗体 |
| AU2006232310B9 (en) | 2005-04-06 | 2011-07-21 | Ibc Pharmaceuticals, Inc. | Improved stably tethered structures of defined compositions with multiple functions or binding specificities |
| US8349332B2 (en) * | 2005-04-06 | 2013-01-08 | Ibc Pharmaceuticals, Inc. | Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases |
| US20120276100A1 (en) * | 2005-04-06 | 2012-11-01 | Ibc Pharmaceuticals, Inc. | Compositions and Methods of Use of Immunotoxins Comprising Ranpirnase (Rap) Show Potent Cytotoxic Activity |
| US9623115B2 (en) * | 2005-04-06 | 2017-04-18 | Ibc Pharmaceuticals, Inc. | Dock-and-Lock (DNL) Complexes for Disease Therapy |
| US8158129B2 (en) * | 2005-04-06 | 2012-04-17 | Ibc Pharmaceuticals, Inc. | Dimeric alpha interferon PEGylated site-specifically shows enhanced and prolonged efficacy in vivo |
| CA2604032C (en) | 2005-04-06 | 2017-08-22 | Ibc Pharmaceuticals, Inc. | Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses |
| US8475794B2 (en) * | 2005-04-06 | 2013-07-02 | Ibc Pharmaceuticals, Inc. | Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases |
| US8481041B2 (en) * | 2005-04-06 | 2013-07-09 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (DNL) constructs for human immunodeficiency virus (HIV) therapy |
| CA2607056C (en) * | 2005-10-19 | 2015-11-24 | Ibc Pharmaceuticals, Inc. | Methods and compositions for generating bioactive assemblies of increased complexity and uses |
| CN105709237A (zh) | 2005-12-16 | 2016-06-29 | Ibc 医药公司 | 基于免疫球蛋白的多价生物活性装配体 |
| WO2008033413A2 (en) | 2006-09-14 | 2008-03-20 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| WO2008039432A1 (en) * | 2006-09-26 | 2008-04-03 | Alexion Pharmaceuticals, Inc. | Compositions and methods for enhancing an adjuvant |
| US8057798B2 (en) * | 2007-02-02 | 2011-11-15 | Baylor Research Institute | Vaccines based on targeting antigen to DCIR expressed on antigen-presenting cells |
| WO2010022225A1 (en) * | 2008-08-20 | 2010-02-25 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (dnl) vaccines for cancer therapy |
-
2009
- 2009-08-20 WO PCT/US2009/054441 patent/WO2010022225A1/en not_active Ceased
- 2009-08-20 JP JP2011523987A patent/JP5870404B2/ja active Active
- 2009-08-20 EP EP09808814A patent/EP2326346A4/en not_active Withdrawn
- 2009-08-20 AU AU2009282830A patent/AU2009282830B2/en active Active
- 2009-08-20 CA CA2734265A patent/CA2734265C/en active Active
- 2009-08-20 CN CN200980141590.7A patent/CN102186499B/zh active Active
- 2009-08-20 US US12/544,476 patent/US7901680B2/en not_active Expired - Lifetime
-
2011
- 2011-01-21 US US13/010,993 patent/US9457072B2/en active Active
-
2016
- 2016-08-24 US US15/246,089 patent/US20160361405A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7379561B2 (ja) | キメラ抗原及びt細胞受容体、並びに使用方法 | |
| CA3090793C (en) | MODIFIED MULTIPOTENTED STEM CELLS, AND METHODS OF PREPARATION AND USE | |
| JP7325959B2 (ja) | 腫瘍特異的細胞の枯渇のための抗CD25 FCγ受容体二重特異性抗体 | |
| KR102481922B1 (ko) | T 세포 요법을 위한 진단 방법 | |
| JP2016520548A5 (cg-RX-API-DMAC10.html) | ||
| CN111727373A (zh) | 靶向bcma的嵌合抗原受体及其用途 | |
| JP2018522833A (ja) | キメラ抗原受容体(car)コンストラクト、及びcarコンストラクトを発現するt細胞(car−t)またはnk細胞(car−nk)による疾患治療 | |
| JP2016534092A5 (cg-RX-API-DMAC10.html) | ||
| CN111481667A (zh) | 对cars的抗肿瘤活性的毒性管理 | |
| JP2017533909A (ja) | 非フコシル化抗cd40抗体の投与量および投与 | |
| AU2019314452B2 (en) | Chimeric antigen receptor therapy T cell expansion kinetics and uses thereof | |
| US20240317815A1 (en) | T-cell modulatory multimeric polypeptides and methods of use thereof | |
| US20250019411A1 (en) | T-Cell Engaging Polypeptides and Methods of Use Thereof | |
| WO2024173376A2 (en) | Combination therapy comprising multispecific gamma delta tcr antibodies | |
| EP4003375A1 (en) | Depletion regimes for engineered t-cell or nk-cell therapy | |
| US20250161355A1 (en) | Proteins for modulating cell therapy products and methods of use thereof | |
| WO2025064716A1 (en) | T-cell modulatory polypeptides and methods of use thereof | |
| WO2025064715A1 (en) | T-cell modulatory polypeptides and methods of use thereof | |
| WO2026019667A1 (en) | Trispecific antibodies for activation of immune cells | |
| NZ786026A (en) | Anti CD25 Fc gamma receptor bispecific antibodies for tumor specific cell depletion | |
| HK1262659A1 (en) | Anti cd25 fc gamma receptor bispecific antibodies for tumor specific cell depletion |